Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates.

The metabolism of toborinone, (+/-)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quin - olinone, a novel inotropic agent, was studied in rats and dogs after intravenous administration. Chemical structures of the 13 metabolites were characterized by direct-probe FAB/MS and field desorption/MS, LC/FAB/MS, and various NMR measurements. After intravenous dosing of 10 mg/kg [14C]toborinone, fecal and urinary recoveries of the 14C dose were approximately 70% and 26-30%, respectively, in both rats and dogs. The predominant component of radioactivity was the unchanged toborinone in every biological specimen in rats and dogs. Although unchanged toborinone was predominantly observed, toborinone underwent extensive conjugations with glucuronic acid, sulfate, and glutathione, either directly or following phase I reaction. Metabolites resulting from oxidative N-C cleavage were minor both in number and in quantity in every biological specimen in rats and dogs. In rats, toborinone underwent O-demethylation to form M-7 and successive phase it reaction to yield the glucuronide M-1 and the sulfoconjugate M-2, and deconjugation to yield M-7, which was a primary metabolite accounted for 35.67% of the radioactivity excreted in the feces by 48 hr. Conjugates M-1 and M-2 were the major metabolites in rat plasma. In dogs, toborinone was metabolized via mercapturic acid pathway to yield the primary metabolites, cysteine conjugates M-10 and M-11 that accounted for 19.10% and 6.70% of the radioactivity excreted in the feces by 48 hr and that were detected species specifically in dogs. The glutathione conjugate M-13, which was isolated from in vitro incubations using dog liver, led us to consider a possible mercapturic acid pathway from the parent compound to M-10. Metabolites in dog plasma and those in urine in both rats and dogs were minor in quantity. The metabolic pathways of toborinone in rats and dogs are proposed herein.

[1]  M. Tateishi,et al.  Chapter 6 – Cysteine Conjugate β-Lyase , 1980 .

[2]  K. Rajagopalan.  Chapter 14 – Xanthine Oxidase and Aldehyde Oxidase , 1980 .

[3]  William B. Jakoby,et al.  Enzymatic basis of detoxication , 1980 .

[4]  A. Hirayama,et al.  Pharmacokinetics and Pharmacodynamics of Intravenous OPC‐18790 in Humans: A Novel Nonglycosidic Inotropic Agent , 1994, Journal of clinical pharmacology.

[5]  T. Walle,et al.  Quantitative account of propranolol metabolism in urine of normal man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[6]  A. D. Jones,et al.  In vivo metabolism of isomeric naphthalene oxide glutathione conjugates. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[7]  B. J. Bradbury,et al.  Mammalian metabolism of phencyclidine. , 1981, Journal of medicinal chemistry.

[8]  C. Klaassen,et al.  Species variations in biliary excretion of glutathione-related thiols and methylmercury. , 1988, Toxicology and applied pharmacology.

[9]  S. Nelson,et al.  Quantitative determination of the glutathione, cysteine, and N-acetyl cysteine conjugates of acetaminophen by high-pressure liquid chromatography. , 1977, Analytical biochemistry.

[10]  H. Eklund,et al.  3 Alcohol Dehydrogenases , 1975 .

[11]  Edward J. Calabrese,et al.  Principles of animal extrapolation , 1983 .

[12]  K. Midha,et al.  Cis-flupentixol metabolites in rat plasma and bile. The first proof of glutathione conjugation at the exocyclic double bond. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[13]  D. Benziger,et al.  Metabolism of amrinone in animals. , 1982, Drug Metabolism And Disposition.

[14]  A. Shulkes,et al.  Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver. , 1995, Drug Metabolism And Disposition.

[15]  C. Nguyen,et al.  Phencyclidine metabolism in vitro. The formation of a carbinolamine and its metabolites by rabbit liver preparations. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Toyoki Mori,et al.  Differential effects of OPC‐18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea‐pig isolated ischaemic heart , 1995, British journal of pharmacology.

[17]  M. Green,et al.  Studies on the fate of the glutathione and cysteine conjugates of acetaminophen in mice. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[18]  R. Zamboni,et al.  Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1). , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[19]  R. Silverstein,et al.  Spectrometric identification of organic compounds , 2013 .

[20]  C. Klaassen,et al.  Mechanisms of bile formation, hepatic uptake, and biliary excretion. , 1984, Pharmacological reviews.

[21]  H. Fujiki,et al.  Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study. , 1995, Cardiovascular research.

[22]  D. Jerina,et al.  Stereoselectivity of cytochrome P-450c in the formation of naphthalene and anthracene 1,2-oxides. , 1984, The Journal of biological chemistry.

[23]  T. Baillie,et al.  Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[24]  T. Little,et al.  METABOLISM OF PHENCYCLIDINE. THE ROLE OF THE CARBINOLAMINE INTERMEDIATE IN THE FORMATION OF LACTAM AND AMINO ACID METABOLITES OF NITROGEN HETEROCYCLES , 1985 .